Dr. Johnson will expedite biopharmaceutical industry use of Phesi’s newly launched ClinSite™ clinical trial investigator site selection tool
EAST LYME, Conn.–(BUSINESS WIRE)–#Phesi–Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced the appointment of Otis Johnson, PhD, MPA, as the company’s chief commercial officer. Dr. Johnson’s primary responsibility will be overseeing the growth of Phesi’s full-service offerings, focusing mainly on commercialization of ClinSite™, the company’s recently launched, AI-driven clinical trial investigator site selection tool, available to biopharmaceutical companies as a Software as a Service (SaaS) solution.
“We are thrilled to welcome Dr. Otis Johnson to our growing leadership team, as he is a long-time client, friend, and trusted colleague,” said Phesi Founder and President Gen Li, PhD, MBA. “Otis was one of Phesi’s earliest customers when he was at Merck, where we discovered he shared our vision for a data-led transformation of clinical development across the industry. His expertise in all aspects of our business – clinical research and development, feasibility, site identification, site relationships, patient recruitment, change management, analytics and innovation – will be vital to our customers and our continued growth.”
“I have been watching Phesi evolve over the past decade, and am excited to finally be on the ‘inside’ as chief commercial officer,” said Dr. Johnson. “With its unparalleled talent and entrepreneurial spirit, Phesi is at an important juncture where its technology and expertise match exactly with what the biopharma industry needs and is increasingly ready to adopt. I am eager to expedite industry use of Phesi’s innovative products and services, especially ClinSite™, which enables companies to do their own precise investigator site selection, with or without additional assistance from our team.”
Dr. Johnson started his career as a basic researcher in an immunology lab at New York University (NYU) School of Medicine, then transitioned to clinical research at Merck, where he spent a total of 13 years in various roles including associate director of clinical research and manager of global trial optimization. He then transitioned to the clinical research organization (CRO) field, first serving as vice president of clinical research at Syneos (formerly inVentiv Health), and most recently as a vice president at ICON Clinical Research. At both of those major CROs, Dr. Johnson was instrumental in transforming the companies’ feasibility groups, led numerous restructurings and growth plans, and managed technology upgrades and other key iniatives, winning several awards in the process.
Dr. Johnson has a BS degree in Medical Laboratory Sciences from Hunter College, a Master of Public Administration (MPA) in Health Policy and Management from NYU, and a PhD in Management from Walden University, with a specialization in Leadership and Organizational Change. He also recently completed a certification course at MIT in Artificial Intelligence Strategy: Implications for Business.
Phesi provides comprehensive clinical development analytical products and services for biopharmaceutical companies around the world. The company’s integrated offerings cover the entire clinical development process — from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management. Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools, consisting of 330,000 completed clinical trials, 604,000 completed research projects, 4.2 million physicians and 1.8 million investigator records.